NR2F6 and neoplasm: Pursuing this concept, and mirroring in principle a pharmacological treatment, therapeutic adoptive transfer (ACT) of acute Nr2f6 gene-edited autologous CD3+ T cells into tumor-bearing mice in a combinatorial CTLA-4 or PD-L1 blockade setting was carried out (Fig. 4a).